Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.45 |
| ▸ | MERTK | Q12866 | 5/20 | 0.45 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014077 | 0.82 | SMYD3 (0.48) | FLT3TYRO3MERTKGAS6CRHR1 | |
| SCHEMBL1013682 | 0.77 | LMNA (0.54) | HPGDNR3C1SPRLMNA | |
| SCHEMBL1016181 | 0.75 | LMNA (0.56) | HPGDNR3C1LMNA | |
| SCHEMBL1014942 | 0.75 | LMNA (0.56) | HPGDNR3C1LMNA | |
| SCHEMBL1017876 | 0.75 | LMNA (0.56) | HPGDNR3C1LMNA | |
| SCHEMBL1012872 | 0.75 | PTPN11 (0.52) | FLT3TYRO3MERTKGAS6AXL | |
| SCHEMBL1014893 | 0.74 | MEN1 (0.51) | HPGDLMNA | |
| SCHEMBL1014078 | 0.72 | HPGD (0.56) | FLT3TYRO3MERTKGAS6HPGD | |
| SCHEMBL541539 | 0.72 | FLT3 (0.53) | FLT3TYRO3MERTKGAS6HPGD | |
| SCHEMBL1018675 | 0.71 | HPGD (0.55) | FLT3TYRO3MERTKGAS6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | FLT3 894/4885TYRO3 4281/4885MERTK 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.